Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Dysautonomia in Long Haul Covid-19 Infection Impairs Activities of Daily Living and Mental Health: The Patient Perspective
Infectious Disease
P9 - Poster Session 9 (5:30 PM-6:30 PM)
4-004

Dysautonomia is an established neurological effect of COVID-19 and has been reported in long-haul COVID-19 patients. It is imperative to understand the impact of this condition from the patient perspective to appreciate individual illness experience, clinical course, and disease burden to develop neurological, psychiatric, and social interventions.


We report the burden of long haul COVID-19 associated dysautonomia and emphasize impact on activities of daily living and mental health, with the goal of developing interventions.


18 long-haul patients in a COVID-19 Remote Patient Monitoring Program (Precision Recovery: Mount Sinai Health System) were interviewed regarding their experience with COVID-19. Patients were asked about their experiences navigating diagnoses, the health care system, and their recovery process, with emphasis on long-haul symptom course and impact. References to dysautonomia within their long haul COVID-19 experience (symptoms persisting greater than four weeks post initial infection) were analyzed for statistical and qualitative significance. 


The following symptoms of long-haul COVID-19 dysautonomia were reported: fluctuating fevers 12/18 (67%); heart palpitations/tachycardia: 12/18 (67%); digestion problems 8/18 (44%); dizziness 6/18 (33%); and fluctuations in blood pressure 4/18 (22%). 7/18 (39%) of patients reported 3 or more dysautonmic symptoms. Patients reported three categories of impact on daily activities: (1) routine physical exertion intolerance; (2) impaired ability to care for self (nutrition, hygiene); and (3) impacted social interaction due to physical impedance and/or isolation in experience. The main mental health effects associated with long-haul dysautonomia included: (1) depression and suicide ideation, (2) intense anxiety, and (3) self doubt.  


Dysautonomia in long haul COVID-19 patients has a devastating impact on daily living and mental health. It is imperative to recognize these effects and understand them from the patient perspective in order to develop compassionate, validating, and efficacious neurological, psychological, and social interventions for this population. 


Authors/Disclosures
Emma Reford
PRESENTER
Ms. Reford has nothing to disclose.
Nicki Mohammadi Nicki Mohammadi has nothing to disclose.
Natalia Romano Spica Ms. Romano Spica has nothing to disclose.
Jenna Tosto, PT (Mount Sinai Health-Abilities Research Center) Dr. Tosto has nothing to disclose.
Laura Rosenbaum Tabacof, MD (Icahn School of Medicine at Mount Sinai) Dr. ROSENBAUM TABACOF has nothing to disclose.
David Putrino, PT,PhD (Icahn School of Medicine at Mount Sinai) An immediate family member of Dr. Putrino has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Psilobrain, LLC. Dr. Putrino has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Thorne Healthtech. Dr. Putrino has received stock or an ownership interest from Precision Recovery, Inc. The institution of Dr. Putrino has received research support from National Institutes of Health. The institution of Dr. Putrino has received research support from New York State Spinal Cord Injury Research Board. The institution of Dr. Putrino has received research support from Gondola, Inc. The institution of Dr. Putrino has received research support from SimpleTherapy, Inc. The institution of Dr. Putrino has received research support from CelloScope. Dr. Putrino has received intellectual property interests from a discovery or technology relating to health care. Dr. Putrino has received intellectual property interests from a discovery or technology relating to health care. Dr. Putrino has received intellectual property interests from a discovery or technology relating to health care. Dr. Putrino has received intellectual property interests from a discovery or technology relating to health care. Dr. Putrino has received publishing royalties from a publication relating to health care.
Christopher Paul Kellner, MD (Mount Sinai Health System) Dr. Kellner has stock in METIS Innovative. Dr. Kellner has stock in Precision Recovery. Dr. Kellner has stock in Synchron. Dr. Kellner has stock in Fluid BioMed. Dr. Kellner has stock in Proprio. Dr. Kellner has stock in Von Vascular. Dr. Kellner has stock in E8. Dr. Kellner has stock in Borvo. Dr. Kellner has stock in Phantom Neuro. The institution of Dr. Kellner has received research support from Integra. The institution of Dr. Kellner has received research support from Penumbra. The institution of Dr. Kellner has received research support from Viz.AI. The institution of Dr. Kellner has received research support from ICE Neurosystems. The institution of Dr. Kellner has received research support from Irras. The institution of Dr. Kellner has received research support from Microtransponder. The institution of Dr. Kellner has received research support from Medtronic. The institution of Dr. Kellner has received research support from Longeviti. The institution of Dr. Kellner has received research support from Endostream. The institution of Dr. Kellner has received research support from CVAID.